Critical Contrast: Senti Biosciences (NASDAQ:SNTI) versus Ginkgo Bioworks (NYSE:DNA)

Ginkgo Bioworks (NYSE:DNA) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Profitability

This table compares Ginkgo Bioworks and Senti Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-298.78%	-58.54%	-34.24%
Senti Biosciences	N/A	-154.84%	-77.42%

Risk & Volatility

Ginkgo Bioworks has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Senti Biosciences has a beta of 2.42, suggesting that its stock price is 142% more volatile than the S&P 500.

Insider & Institutional Ownership

78.6% of Ginkgo Bioworks shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 9.7% of Ginkgo Bioworks shares are held by company insiders. Comparatively, 15.9% of Senti Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Ginkgo Bioworks and Senti Biosciences”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$251.46 million	2.47	-$892.87 million	($13.08)	-0.83
Senti Biosciences	$2.56 million	8.37	-$71.06 million	($15.56)	-0.30

Senti Biosciences has lower revenue, but higher earnings than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for Ginkgo Bioworks and Senti Biosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	3	1	1	0	1.60
Senti Biosciences	0	0	1	0	3.00

Ginkgo Bioworks presently has a consensus price target of $4.58, suggesting a potential downside of 57.70%. Senti Biosciences has a consensus price target of $10.00, suggesting a potential upside of 114.13%. Given Senti Biosciences’ stronger consensus rating and higher possible upside, analysts clearly believe Senti Biosciences is more favorable than Ginkgo Bioworks.

Summary

Senti Biosciences beats Ginkgo Bioworks on 7 of the 12 factors compared between the two stocks.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

About Senti Biosciences

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.